Harmony Biosciences Inc.

1 day ago · defenseworld.net

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 800 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $43.00, for a total transaction of $34,400.00. Following the completion of the transaction, the insider directly owned 13,115 shares in

2 days ago · defenseworld.net

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 1,800 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $43.01, for a total transaction of $77,418.00. Following the completion of the transaction, the insider directly owned 13,115 shares in

19 days ago · zacks.com

Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?

1 month ago · defenseworld.net

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 65,148 shares of the company's stock, valued at approximately $2,372,000. Harmony Biosciences accounts for approximately 1.2% of

1 month ago · marketbeat.com

Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.

2 months ago · seekingalpha.com

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.

2 months ago · zacks.com

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

2 months ago · zacks.com

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

2 months ago · seekingalpha.com

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Harmony Biosciences NASDAQ: HRMY reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year.